These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29754968)

  • 1. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
    Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
    J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
    Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
    Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
    Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
    Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
    Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
    Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and
    Wirsching HG; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P; Ochsenbein A; Tabatabai G; Weller M
    Clin Cancer Res; 2021 Jan; 27(1):179-188. PubMed ID: 32967939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Early Postoperative O-(2-
    Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
    World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
    BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular architecture mapping for early detection of glioblastoma recurrence.
    Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
    Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-(2-(
    Mihovilovic MI; Kertels O; Hänscheid H; Löhr M; Monoranu CM; Kleinlein I; Samnick S; Kessler AF; Linsenmann T; Ernestus RI; Buck AK; Lapa C
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):238-239. PubMed ID: 29705720
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudoprogression on 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT in a Treated Glioblastoma.
    Gupta M; Choudhury PS; Gairola M; Premsagar IC; Rao SA
    Clin Nucl Med; 2020 Aug; 45(8):621-622. PubMed ID: 32520501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.
    Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F
    World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.